跳至主要内容
临床试验/CTRI/2017/08/009200
CTRI/2017/08/009200已完成2 期

CLINICAL EVALUATION OF NAVAYASA CHURNA IN THE MANAGEMENT OF IRON DEFICIENCY ANAEMIA

Central Council for Research in Ayurvedic Sciences0 个研究点目标入组 50 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
已完成
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1) Patients of either sex aged between 18 to 50 years.
  • 2) Patients with iron deficiency anaemia (Hb 8gm-10gm. %),
  • 3) S. Ferritin < 30 μg /L
  • 4) Patients with peripheral blood smear suggestive of Iron deficiency Anaemia
  • 5) Willing and able to participate for 120 days.

排除标准

  • 1. Patients suffering from Thalassemia major / Aplastic anaemia / Sickle cell anaemia.
  • 2. Patients with evidence of malignancy.
  • 3. Stool examination found with positive ova/cyst/parasite of worm infestation.
  • 4. Patients suffering from major systemic illness necessitating long term drug treatment (Rheumatoid arthritis, Psycho-Neuro-Endocrinal disorders, Bleeding disorders, etc.)
  • 5. Patients who have a past history of Atrial Fibrillation, Coronary Artery Disease (CAD), Acute Coronary Syndrome, Myocardial Infarction, Stroke or Severe Arrhythmia in the last 6 months.
  • 6. Symptomatic patient with clinical evidence of Heart failure.
  • 7. Patients with poorly controlled Hypertension ( > 160 / 100 mm Hg)
  • 8. Patients suffering from Diabetes Mellitus (F.B.S. > 250 mg/dl.)
  • 9. Patients on prolonged ( > 6 weeks) medication with corticosteroids, antidepressants, anticholinergics, etc. or any other drugs that may have an influence on the outcome of the study.
  • 10. Patients with concurrent serious hepatic disorder (defined as Aspartate Amino
  • Transferase (AST) and / or Alanine Amino Transferase (ALT), Total Bilirubin, Alkaline Phosphatase (ALP) > 2 times upper normal limit), or Renal Disorders (defined as S. Creatinine >1.2mg/dL), Total Serum Cholesterol & / or Serum Triglycerides > 250 mg/dl, Severe Pulmonary Dysfunction (uncontrolled Bronchial Asthma and / or Chronic Obstructive Pulmonary Disease [COPD]).
  • 11. Alcoholics and/or drug abusers.
  • 12. Pregnant / lactating woman
  • 13. H/o hypersensitivity to the trial drug or any of its ingredients.
  • 14. Patients who have completed participation in any other clinical trial during the past six (06) months.
  • 15. Any other condition which the Investigator thinks may jeopardize the study.

研究者

相似试验